Tuesday 23 October l 2:30 pm (SAST, Harare Pretoria)
Tuberculosis (TB) infection significantly affects the human immune system. This, however, provides an opportunity to study the immune system modulation to identify markers especially for latent phase and non-lung infection. Additionally, changes in the host immune response could be sensitive indicators of mycobacterial killing by treatment and might give insight into the immune dysregulation in TB patients reflecting therapy response.
Among the methods used in TB research a new combination of gene expression profiling and systems biology analysis has recently been utilized for the biomarker research and therapy progression analysis.
In this webinar we are going to discuss how high-throughput experimental approach and pathway analysis can be complemented with associated long-term clinical annotation comprising drug response and expression changes in patients based on recent scientific publications.
This webinar will help you
Alexey Dubovenko graduated from the School of Bioengineering and Bioinformatics at Moscow State University. Over the last 10 years he has worked in biological data analysis including the biological interpretation of OMICs data in different therapeutic areas, personalized treatment selection in oncology, mathematical modeling of treatment efficacy, toxicity, pharmacokinetics and pharmacodynamics on preclinical and clinical phases for top pharmaceutical companies. Alexey became the Discovery Sciences Product Manager at Clarivate Analytics in 2015.
